使用聚(D,L-丙交酯-共-乙交酯)及其衍生物递送大分子治疗药物的纳米/微技术
Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives.
作者信息
Mundargi Raghavendra C, Babu V Ramesh, Rangaswamy Vidhya, Patel Pradip, Aminabhavi Tejraj M
机构信息
Industrial Biotechnology Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Centre, Thane Belapur Road, Rabale, Navi Mumbai 400 701, India.
出版信息
J Control Release. 2008 Feb 11;125(3):193-209. doi: 10.1016/j.jconrel.2007.09.013. Epub 2007 Oct 22.
Biodegradable nano/microparticles of poly(D,L-lactide-co-glycolide) (PLGA) and PLGA-based polymers are widely explored as carriers for controlled delivery of macromolecular therapeutics such as proteins, peptides, vaccines, genes, antigens, growth factors, etc. These devices are mainly produced by emulsion or double-emulsion technique followed by solvent evaporation or spray drying. Drug encapsulation, particle size, additives added during formulation, molecular weight, ratio of lactide to glycolide moieties in PLGA and surface morphology could influence the release characteristics. Encapsulation efficiency and release rates through nano/microparticle-mediated drug delivery devices can be optimized to improve their therapeutic efficacy. In this review, important findings of the past decade on the encapsulation and release profiles of macromolecular therapeutics from PLGA and PLGA-based nano/microparticles are discussed critically in relation to nature and type of bioactive molecule, carrier polymer and experimental variables that influence the delivery of macromolecular therapeutics. Even though extensive research on biodegradable microparticles containing macromolecular drugs has greatly advanced to the level of production know-how, the effects of critical parameters influencing drug encapsulation are not sufficiently investigated for nano-scaled carriers. The present review attempts to address some important data on nano/microparticle-based delivery systems of PLGA and PLGA-derived polymers with reference to macromolecular drugs.
聚(D,L-丙交酯-共-乙交酯)(PLGA)及其基聚合物的可生物降解纳米/微粒作为蛋白质、肽、疫苗、基因、抗原、生长因子等大分子治疗药物的控释载体被广泛研究。这些制剂主要通过乳液或复乳技术,随后进行溶剂蒸发或喷雾干燥来制备。药物包封、粒径、制剂过程中添加的添加剂、分子量、PLGA中丙交酯与乙交酯部分的比例以及表面形态都会影响释放特性。通过纳米/微粒介导的药物递送装置的包封效率和释放速率可以进行优化,以提高其治疗效果。在本综述中,批判性地讨论了过去十年中关于从PLGA及其基纳米/微粒中包封和释放大分子治疗药物的重要发现,这些发现与生物活性分子的性质和类型、载体聚合物以及影响大分子治疗药物递送的实验变量有关。尽管对含有大分子药物的可生物降解微粒的广泛研究已大大推进到生产技术水平,但对于纳米级载体,影响药物包封的关键参数的作用尚未得到充分研究。本综述试图参考大分子药物,阐述一些关于PLGA及其衍生聚合物的基于纳米/微粒的递送系统的重要数据。